Core Insights - Actuate Therapeutics is advancing elraglusib, a first-in-class GSK-3 inhibitor, targeting multiple difficult-to-treat cancers including mPDAC, melanoma, colorectal cancer, and sarcomas [1][11] - The company is focusing on a dual formulation strategy with both intravenous and oral versions of elraglusib, enhancing its commercial appeal and patient compliance [2][10] Pediatric Breakthroughs - Actuate reported promising phase 1 data from the Actuate-1902 trial involving 40 children and adolescents, achieving complete responses in relapsed/refractory metastatic Ewing sarcoma and neuroblastoma [3][4] - The FDA granted Rare Pediatric Disease Designation for elraglusib, making the company eligible for a Priority Review Voucher (PRV) upon approval of a New Drug Application [4][5] Value of PRVs - PRVs have been sold at premium prices, with recent transactions averaging between $150 million and $200 million, providing significant non-dilutive capital opportunities for small-cap companies like Actuate [6][10] - The PRV program incentivizes the development of treatments for rare pediatric diseases, potentially accelerating revenue generation for Actuate [5][6] RAS Inhibitor Strategy - Actuate is launching a research initiative to evaluate elraglusib in combination with emerging RAS-targeted therapies, addressing adaptive resistance seen in RAS-driven cancers [7][10] - The combination of elraglusib with RAS inhibitors could enhance treatment efficacy by overcoming resistance mechanisms and improving patient outcomes [8][10] Strategic Outlook - Actuate is entering a high-impact period with multiple catalysts, including positive pediatric data, an advancing oral formulation, and a new RAS combination program [10][12] - The potential monetization of a PRV could provide immediate capital, while ongoing research opens avenues for broader market opportunities and collaborations [10][12]

Core Insights - Actuate Therapeutics, Inc. has launched an expanded research initiative to evaluate the combination of its GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies to enhance treatment for difficult-to-treat cancers [1][2] Group 1: Research Initiative - The initiative aims to address adaptive resistance mechanisms in RAS-targeted therapies, which are significant barriers to achieving durable responses in patients [2] - GSK-3β inhibition may enhance RAS-targeted therapies by suppressing downstream survival signaling and resistance pathways, potentially improving clinical outcomes in RAS-driven cancers [2][6] Group 2: Elraglusib Overview - Elraglusib is a highly selective GSK-3β inhibitor with potential applications across various oncology indications, including pancreatic cancer, melanoma, colorectal cancer, and sarcoma [3] - The investigational drug has been administered to over 500 patients and is currently in a Phase 2 trial for metastatic pancreatic cancer [3] Group 3: Combination Strategy - The combination strategy aims to block proliferative signaling through RAS inhibition while disrupting tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic signaling [4] - The program will include in-vitro studies, in-vivo tumor regression and survival studies, and translational biomarker analysis, with initial data expected in Q2 2026 [5][6] Group 4: Future Development - The company is collaborating with leading academic institutions and potential industry partners to advance elraglusib as a foundational component of next-generation treatment paradigms for RAS-driven cancers [6] - Preclinical combination results are anticipated in the second half of 2026, which will inform future clinical development plans [8]

Core Viewpoint - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1] Company Overview - Actuate's lead investigational drug, elraglusib, is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments [4] - Elraglusib may also enhance anti-tumor immunity by regulating multiple immune checkpoints and immune cell functions [4] Upcoming Events - Dan Schmitt, President & CEO of Actuate, will present at the Citizens Life Sciences Conference in Miami Beach, FL on March 10, 2026, at 8:25 a.m. ET [1] - A live webcast of the presentation will be available on Actuate's website, with a replay accessible for 30 days following the event [3]

Core Viewpoint - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through the inhibition of GSK-3β, with a presentation scheduled at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 [1] Company Overview - Actuate Therapeutics is dedicated to creating therapies for high-impact cancers, with its lead investigational drug, elraglusib, targeting molecular pathways that promote tumor growth and resistance to conventional treatments [4] - Elraglusib functions as a GSK-3β inhibitor and may enhance anti-tumor immunity by regulating immune checkpoints and immune cell function [4] Presentation Details - Dan Schmitt, President & CEO of Actuate, will present at the Oppenheimer conference at 9:20 a.m. ET on February 26, 2026 [1] - A webcast of the presentation will be available, and a replay will be accessible on the company's website for 30 days following the event [2][3] - The management team will also conduct one-on-one meetings with investors during the conference [2]

Core Insights - Actuate Therapeutics is advancing the clinical development of elraglusib for Ewing sarcoma and potentially neuroblastoma, having received Rare Pediatric Designations from the FDA for both indications [1][3] Study Overview - The Actuate-1902 trial is an open-label, multicenter phase 1/2 study involving 40 pediatric patients aged 3 to 21 with relapsed or refractory cancers, including Ewing sarcoma and neuroblastoma [2][8] - The primary goal of the phase 1 portion was to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of elraglusib, with initial evidence of anti-tumor activity observed [8] Clinical Results - The phase 1 trial showed clinical responses in relapsed/refractory Ewing sarcoma, with two Complete Metabolic Responses (CMRs) in patients and one Complete Response (CR) in a neuroblastoma patient [6][3] - Overall, clinical responses and disease control were observed in 15 out of 40 patients with difficult-to-treat pediatric cancers, including 10 of 19 patients treated with elraglusib plus cyclophosphamide/topotecan [6][7] Future Plans - The company plans to initiate additional clinical trials in 2026 to expedite a registration pathway for elraglusib in Ewing sarcoma and potentially advance its use in neuroblastoma [4][3] - Collaborative development programs are being assessed with leading pediatric consortia and Key Opinion Leaders to align future studies with patient needs and regulatory expectations [3] Mechanism of Action - Elraglusib is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer therapies, potentially mediating anti-tumor immunity [12]

Core Insights - Actuate Therapeutics, Inc. announced that data from its Phase 2 study of elraglusib in metastatic pancreatic cancer will be presented at the 2026 ASCO GI Cancers Symposium [1] - The study evaluates elraglusib in combination with gemcitabine/nab-paclitaxel, a standard chemotherapy regimen for this type of cancer [1] Presentation Details - Oral Presentation: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma [2] - Date/Time: January 9, 2026, 4:15 PM-5:00 PM (PST) [2] - First Author: Devalingam Mahalingam, MD, PhD, Gastrointestinal Oncologist at Northwestern University [2] Poster Presentation - Title: Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with elraglusib and gemcitabine/nab-paclitaxel [3] - Date/Time: January 9, 2026, 11:30 AM-1:00 PM; 5:00 PM-6:00 PM (PST) [4] - First Author: Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics [4] Company Overview - Actuate Therapeutics is focused on developing therapies for high-impact, difficult-to-treat cancers [4] - The lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting pathways involved in tumor growth and resistance to conventional therapies [4]

Core Insights - Actuate Therapeutics, Inc. announced promising results from a Phase II study of elraglusib, showing a median overall survival of 18.6 months and 40% of patients alive at 2 years [1][5][6] Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with elraglusib as its lead investigational drug targeting GSK-3β [8] Study Details - The Phase II study evaluated elraglusib in combination with platinum chemotherapy in patients with advanced, metastatic salivary gland cancers, including adenoid cystic carcinoma [3][7] - The study enrolled 32 patients, with a median progression-free survival of 6.4 months and 27% of patients progression-free at 1 year [5][11] Key Findings - Nuclear GSK-3β expression was significantly higher in responders (50%) compared to non-responders (2%), suggesting its potential as a biomarker for treatment response [3][11] - Among non-ACC patients receiving immune priming followed by cisplatin plus elraglusib, the response rate was 18%, with all responders showing elevated nuclear GSK-3β expression [4][6] Treatment Efficacy - The median overall survival for non-ACC patients was notably higher at 27.8 months, indicating a potential benefit of elraglusib in this subgroup [5] - The combination treatment was well tolerated, with no treatment-related deaths and a low discontinuation rate due to toxicity [11]

Core Insights - Actuate Therapeutics, Inc. is advancing its investigational drug elraglusib for the treatment of metastatic pancreatic cancer, with a recent public offering raising $17.25 million to support its regulatory path and clinical initiatives [1][5] Regulatory Path and Clinical Trials - The company has amended its IND application with updated clinical data from the Actuate-1801 Part 3B trial, which demonstrated a statistically significant improvement in median overall survival for patients receiving elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) compared to GnP alone [2][5] - The ongoing Phase 2 study has enrolled 286 patients, with 22 patients currently in the elraglusib plus GnP arm showing survival follow-up ranging from 20 to 42 months [3][6] - The trial met its primary endpoint, showing a 37% reduction in the risk of death and a doubling of the 12-month survival rate for the elraglusib combination arm [7] Mechanism of Action and Clinical Collaborations - Elraglusib is a GSK-3β inhibitor that may enhance chemotherapy efficacy and regulate anti-tumor immunity, potentially serving as a backbone therapy in pancreatic cancer treatment [8][10] - The company is collaborating with Incyte and UPMC Hillman Cancer Center to explore elraglusib in combination with modified FOLFIRINOX and retifanlimab for advanced pancreatic cancer [4][8] Financial Position and Future Outlook - The recent financing is expected to provide sufficient capital to support corporate initiatives through the second half of 2026, including anticipated interactions with the FDA and EMA regarding elraglusib's regulatory path [5][8] - The company is optimistic about the survival benefits observed with elraglusib and its potential to be combined with various treatment regimens, addressing the limited options available for pancreatic cancer patients [5][8]

Core Viewpoint - Actuate Therapeutics, Inc. has successfully closed a public offering, raising $17.25 million through the sale of 2,464,286 shares of common stock, with a public offering price of $7.00 per share [1]. Company Overview - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β) [5]. - The company's lead investigational drug, elraglusib, targets molecular pathways that promote tumor growth and resistance to conventional cancer treatments, potentially enhancing anti-tumor immunity [5]. Financial Details - The net proceeds from the offering are approximately $15.62 million, which will be used for working capital and general corporate purposes [2]. - The offering was managed by Lucid Capital Markets, with Titan Partners Group acting as a financial advisor [2]. Regulatory Information - The common stock was offered under a shelf registration statement on Form S-3, which has been declared effective by the SEC [3]. - A final prospectus supplement related to the offering has been filed with the SEC and is available on their website [3].

Core Viewpoint - Actuate Therapeutics, Inc. has announced a public offering of 2,142,858 shares of common stock at a price of $7.00 per share, aiming to raise approximately $15.0 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 321,428 shares at the public offering price [1]. - Lucid Capital Markets is the sole book-running manager, while Titan Partners Group serves as the financial advisor for the offering [2]. Group 2: Financial Information - The gross proceeds from the offering are expected to be around $15.0 million before deducting underwriting discounts and commissions [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on therapies for high-impact, difficult-to-treat cancers, specifically through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [6]. - The lead investigational drug, elraglusib, targets molecular pathways that promote tumor growth and resistance to conventional cancer treatments [6].